KPC(SH:600422) HTSC·2026-03-23 02:40Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Views - The company is expected to experience a revenue and profit decline in 2025, with projected revenues of 6.58 billion RMB, a 22% decrease year-on-year, and a net profit of 350 million RMB, down 46% [1][5]. - 2025 is anticipated to be a bottom year for industrial revenue, with expectations for gradual recovery in 2026 due to management changes and inventory destocking [2][5]. - The long-term outlook remains positive, particularly in the silver health sector and specific product categories like blood stasis and emotional health products [1][5]. Summary by Sections Revenue and Profitability - Industrial revenue is projected to decline by 30% to 3.0 billion RMB in 2025, influenced by reduced retail foot traffic and delayed execution of traditional Chinese medicine procurement [2]. - The gross margin for 2025 is expected to be 38.5%, a decrease of 4.0 percentage points year-on-year, primarily due to pressure on high-margin industrial revenue [3]. - The company anticipates a significant drop in net profit margins, with a net profit margin of 6.4%, down 2.5 percentage points year-on-year [3]. Innovation and R&D - Multiple innovative drug projects are progressing, including a Class 1 new drug for ischemic stroke and a Class 2 innovative drug for systemic lupus erythematosus, both in clinical trials [4]. Financial Projections - The company has revised its profit forecasts for 2026-2028, expecting net profits of 350 million RMB, 390 million RMB, and 440 million RMB respectively, reflecting a significant downward adjustment of 51% and 52% for 2026 and 2027 [5][12]. - The target price is set at 16.15 RMB, based on a 35x PE for 2026, which is a premium compared to the industry average of 20x PE [5][12].